Parallax Volatility Advisers
UTMD icon

Parallax Volatility Advisers’s Utah Medical Products UTMD Stock Holding History

Parallax Volatility Advisers’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-504
Closed -$41K – 4276
2017
Q4 		$41K Buy
+504
New +$39.3K ﹤0.01% 3328

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Parallax Volatility Advisers's UTMD Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Utah Medical Products (UTMD) in Q1 2018, closing a stake of 504 shares — an estimated $41K sold.

Parallax Volatility Advisers first reported a position in UTMD in Q4 2017 and held it in 1 quarter. The position peaked at $41K in Q4 2017. 81 funds tracked by Wall St. Rank hold UTMD as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Utah Medical Products position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 504 Utah Medical Products shares in Q1 2018, an estimated $41K.
  • Parallax Volatility Advisers first reported a position in Utah Medical Products in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Utah Medical Products position peaked at $41K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.